Psyence Biomedical Ltd. Expands Australian Clinical Site Network From Three To Five Locations To Support Ongoing Phase IIb Natural Psilocybin Trial

Psyence Biomedical Ltd., a biopharmaceutical company developing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, announced that it has expanded its clinical site network in Australia from three to five locations. This expansion supports the company’s ongoing clinical activities and strengthens its ability to execute its development plans efficiently.

The two new additions—Ramsay Health Care and NeuroCentrix—bring established hospital and specialist research capabilities into Psyence BioMed’s clinical network. Their involvement is expected to enhance operational support, increase site capacity, and add experienced clinical teams familiar with conducting complex psychiatric and palliative care research.

Psyence BioMed’s ongoing Phase IIb clinical trial, managed by Southern Star Research, is evaluating natural psilocybin for treating Adjustment Disorder in cancer patients receiving palliative care. The study is currently active at three initial sites: Empax Centre in Perth, the Mind Medicine Australia Clinic in Melbourne, and Paratus Clinical Research in Melbourne, where the first patient was dosed in late 2025.

With the addition of Ramsay Health Care and NeuroCentrix, the clinical program now spans five sites. This expansion is expected to strengthen patient recruitment, speed up enrollment timelines, and support the continued progression of the multi-site Phase IIb trial involving natural psilocybin in a palliative oncology population.

To support its trial activities, Psyence BioMed is supplying NPX-5—its fully GMP-compliant, pharmaceutical-grade psilocybin product available in 1 mg and 5 mg capsules. NPX-5 is manufactured at the GMP-controlled PsyLabs facility, a private company in which Psyence BioMed has made strategic investments. This manufacturing capability ensures reliable supply for ongoing trials, supports the advancement of NPX-5 as the company’s lead clinical candidate, and enables efficient clinical operations across multiple geographic regions.

Jody Aufrichtig, CEO of Psyence BioMed, noted that expanding the clinical network marks an important step in building the infrastructure necessary to advance NPX-5. He emphasized that adding high-quality partners like Ramsay Health Care and NeuroCentrix strengthens the company’s ability to execute its studies effectively, improve enrollment momentum, and generate meaningful clinical evidence. As patient dosing continues, the company remains focused on advancing the program through a disciplined, regulatory-aligned development pathway.